# Breaking Ground: New Tools in Alzheimer's Diagnosis Newsy: Alzheimer’s News Weekly Published: 2026-08-24T13:30:00.726Z Source: https://newsyai.com/edition/920d9da4-08a0-4fef-a80c-aec801147ee3 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- **Alzheimer’s Treatment Briefing: New Diagnostic Tools and Early Research Signals** **Coverage period: August 17–August 24, 2026** Broad searches across news outlets, research databases, regulatory announcements, and trial registries identified a handful of developments this week, centered on improved diagnostics and early-stage research rather than large new trial readouts. The most relevant updates for treatment involve better tools to detect and stage the disease earlier, plus promising lab findings on potential future therapies. Here are the key stories worth highlighting, ranked by potential impact on care. **1. FDA clears PrecivityAD2 blood test for Alzheimer’s diagnosis in adults as young as 40** **Overview** The U.S. Food and Drug Administration cleared C2N Diagnostics’ PrecivityAD2 blood test, making it available for people showing cognitive symptoms starting at age 40. This is the first such blood test cleared for this younger group. It measures specific Alzheimer’s-related proteins in the blood to help doctors assess whether brain changes consistent with the disease are present. The clearance builds on earlier work and expands access to a simple blood draw instead of more invasive tests.[[1]](https://www.alzdiscovery.org/news-room/announcements) **Why this matters** Think of Alzheimer’s as a slow leak in a pipe that builds up pressure over years before anyone notices a flood. This test acts like an early pressure gauge, helping spot the issue sooner—potentially years before major symptoms appear. Earlier detection means more time to discuss approved treatments, lifestyle steps, or clinical trials while the brain still has more reserves. It supports a shift toward precision care tailored to the individual. **2. FDA approves Tauklarify tau PET imaging agent for Alzheimer’s assessment** **Overview** The FDA approved Tauklarify (florquinitau F 18 injection), a radioactive tracer used in brain PET scans. It helps visualize tau protein buildup (twisted tangles linked to nerve damage) in adults with cognitive impairment being evaluated for Alzheimer’s. The agent is not approved for other tau-related conditions. This adds a targeted imaging option alongside existing amyloid scans.[[2]](https://www.itnonline.com/content/fda-approves-imaging-agent-alzheimers-patients) **Why this matters** Amyloid plaques and tau tangles are like two different types of debris clogging the brain’s highways. Amyloid scans have been available, but seeing tau directly gives doctors a clearer map of how far the disease has progressed in specific brain areas. Better staging can guide decisions on when to start or combine treatments and help track how therapies are working in real time. **3. UCLA researchers identify ALI6 compound that blocks amyloid from harming brain cells** **Overview** University of California, Los Angeles scientists mapped how toxic amyloid-beta proteins latch onto brain cells and identified a compound (ALI6) that interferes with this binding. In cell experiments, ALI6 nearly prevented the cell death caused by amyloid. The molecule appears non-toxic and can reach the brain from the bloodstream. This is early laboratory work; further animal testing is planned before human studies.[[3]](https://www.uclahealth.org/news/release/researchers-discover-drug-that-could-combat-brain-cell-death-in-those-with-alzheimers-disease) **Why this matters** Instead of just trying to vacuum up amyloid after it has already stuck around, this approach aims to stop the “glue” from attaching in the first place—like adding a protective coating to keep debris from clumping on delicate surfaces. If successful in later stages, it could offer a new way to protect neurons early, potentially complementing existing plaque-clearing drugs. **What this means for care right now** - Talk with your doctor about blood tests or imaging if cognitive changes are a concern; newer options may improve diagnosis accuracy and speed. - Approved treatments like lecanemab (Leqembi) and donanemab (Kisunla) remain options for eligible early-stage patients with confirmed amyloid. - Lifestyle factors (heart health, exercise, sleep, and social engagement) and clinical trial participation continue to be important supports for brain health. - Watch for more data at upcoming conferences. **Sources** - Alzheimer’s Drug Discovery Foundation announcement on PrecivityAD2 clearance (August 20, 2026). - iTNonline and related reports on Tauklarify FDA approval (around August 14–20, 2026). - UCLA Health news release on ALI6 compound (August 19, 2026). - Comprehensive web searches for Alzheimer’s news, trials, and regulatory announcements covering August 17–24, 2026 (conducted August 24, 2026). New diagnostic tools and early mechanistic insights continue to expand the foundation for more timely and targeted Alzheimer’s care.